Peptide-based therapies have re-entered industry and regulatory conversations in recent months, prompting questions across clinical and pharmacy settings about what is actually changing and what is not. The increased visibility is not tied to a single regulatory decision, but rather to a convergence of ongoing FDA review, sustained clinical demand, and greater scrutiny around sourcing practices. Read More >
ProRx Pharma is an FDA-registered 503B facility focused on providing essential compounded sterile and non-sterile preparations. The company compounds products and formulations for medical institutions, physician offices, and 503A pharmacies, with a specialization in producing high-quality products to ensure patients have access to the medications they need during critical shortages.
This post is related to:
